<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716547</url>
  </required_header>
  <id_info>
    <org_study_id>CL-033-III-03</org_study_id>
    <nct_id>NCT00716547</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Study of Safety and Efficacy of Two Dosages of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDEA AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDEA AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide replicated evidence of safety and efficacy of 50 mg
      and 100 mg ketoprofen in Diractin®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will investigate safety and efficacy of 2 dosages of Diractin®at relieving the
      signs and symptoms of knee OA, including the primary endpoint of patient assessment of pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain subscale of the WOMAC</measure>
    <time_frame>week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment of response to therapy</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>function subscale of the WOMAC</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1399</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoprofen in Diractin®</intervention_name>
    <description>50 mg (b.i.d.)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoprofen in Diractin®</intervention_name>
    <description>100 mg (b.i.d.)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>b.i.d.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>100 mg (b.i.d.)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent signed and dated

          -  Age &gt; 45 years

          -  Class I-III OA of the knee and subject meets American College of Rheumatology (ACR)
             clinical classification criteria for osteoarthritis of the knee

        Exclusion Criteria:

          -  Skin lesions or dermatological diseases in the treatment area

          -  Directly or indirectly involved in the conduct and administration of this study

          -  Received any investigational medicinal product within 30 days prior to Screening Visit
             or participation in any previous clinical study with Diractin®

          -  Pregnancy or lactation

          -  Residents of psychiatric wards, prisons or other state institutions

          -  Malignancy within the past 2 years

          -  Depressive disorders requiring treatment with tricyclics, treatment with other
             antidepressants must be stable for 3 months prior to screening and throughout the
             study

          -  Epilepsy

          -  Schizophrenia

          -  Neuropathic pain and any other pain condition requiring chronic use of pain medication

          -  Known hypersensitivity or allergy (including photoallergy) to NSAID´s including
             ketoprofen, celecoxib, sulfonamides and ingredients used in pharmaceutical products
             including galactose

          -  Peripheral arterial disease and/or cerebrovascular disease

          -  History of stroke or myocardial infarction

          -  Congestive Heart failure NYHA Class II-IV

          -  History of pancreatitis or peptic ulcers;

          -  Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)

          -  Serum creatinine levels &gt; 2.5 milligrams/deciliter (mg/dL)

          -  ALT or AST levels ≥ 5 times the ULN

          -  Unable to discontinue analgesic therapy including opioids, NSAID´s, tramadol, muscle
             relaxants, gabapentin, pregabalin, duloxetine, venlafaxine, capsaicine or other drugs
             approved or used for the treatment of pain for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>IDEA AG Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>IDEA AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IDEA Investigational Site</name>
      <address>
        <city>Prague 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaus-Miehlke-Klinik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Claudia Himly / Director of Clinical Operations</name_title>
    <organization>IDEA AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

